2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2715

Genetic Variants in TNF, TNFRSF1A, and IL23R Are Associated with Risk of Ankylosing Spondylitis
Abstract Number: 2716

Does Secretory Immunoglobulin a Influence Disease Activity in Patients with Reactive Arthritis and Undifferentiated Spondylarthritis?
Abstract Number: 2717

Sclerostin and Dickkopf-1 but Not Periostin May Have a Role in Psoriatic Arthritis
Abstract Number: 2718

Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis
Abstract Number: 2719

Discriminating Value of Calprotectin in Disease Activity and Progression of Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
Abstract Number: 2720

Genome-Wide Association Study of Clinical Phenotypes in Psoriatic Arthritis
Abstract Number: 2721

Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 2722

Evolution over Thirty Years of the Profile of Inpatients with Reactive Arthritis in a Tertiary Rheumatology Unit
Abstract Number: 2723

The Co-Occurrence of Axial Spondyloarthritis and Fibromyalgia: A National Register-Based Study
Abstract Number: 2724

A Prospective Study of Ankylosing Spondylitis in China with Smart Management System for Spondyloarthritis: Study Design and Baseline Characteristics of the 449 Recruited Patients
Abstract Number: 2725

Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies
Abstract Number: 2726

Prevalence of HLA-B27 in the Normal Population and Patients with Axial Spondyloarthritis in Saudi Arabia
Abstract Number: 2727

Evaluating Psoriatic Arthritis and Psoriasis Skin Lesions: Ultrasound As a Complementary Measure
Abstract Number: 2728

Discontinuation of Biologic Therapy in Patients with Ankylosing Spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 2729

Treatment Patterns, Unmet Need, and Impact of Psoriatic Arthritis on Patient-Reported Outcomes in the United States

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].